LEAD PLAINTIFF DEADLINE IS JUNE 27, 2022
NEW YORK, May 13, 2022 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Natera, Inc. ("Natera") NTRA on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the "Class Period").
All investors who purchased the shares of Natera, Inc. and incurred losses are advised to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.
If you have incurred losses in Natera, Inc. you may, no later than June 27, 2022, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Natera, Inc.
PLEASE CLICK HERE TO JOIN THE CASE
On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, including Natera's Panorama test, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy.
On this news, Natera's stock price fell $5.35, or 5.7%, over two trading days to close at $88.04 per share on January 4, 2022.
Then, on January 14, 2022, a nonprofit watchdog group filed a complaint with the SEC requesting an investigation into whether Natera had "repeatedly" claimed that its tests were "much more reliable than it appears they really are."
On this news, Natera's stock fell $6.29, or 9.3%, to close at $61.08 per share on January 18, 2022.
On March 9, 2022, Hindenburg Research published a report which alleged, among other things, that Natera's revenue growth has been "fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers." On this news, Natera's stock price fell $17.95, or 32.8%, to close at $36.80 per share on March 9, 2022.
Then, on March 14, 2022, a Delaware District Court jury found that Natera had engaged in false advertising, including claims that its kidney transplant test, Prospera, was more accurate than its competing tests. On this news, Natera's stock price fell $5.57 per share, or 15.5%, to close at $30.32 per share on March 15, 2022.
Then, on April 19, 2022, the United States Food and Drug Administration ("FDA") issued a safety communication "to educate patients an health care providers and to help reduce the inappropriate use" of non-invasive prenatal tests ("NIPT"), cautioning that NIPTs reliability and accuracy "may not be supported with sound scientific evidence," revealing that there had been "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy. On this news, Natera's stock fell $1.53, or 3.9%, to close at $38.63 per share on April 19, 2022.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
